Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsNA

Crainio Non-invasive ICP Monitor for TBI

Sponsor: Crainio Ltda

NCT ID: NCT06453733

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Crainio (device)
How long the study runs
Study runs about 19 months (dates as stated)
About the drug or intervention
Crainio — device: Crainio device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe.
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
16 Years to 99 Years
Who
All
Number of participants
54
Started
2025-05-15
Last checked
2026-03

Plain English Summary

What is this study?

  • • Testing a new treatment for traumatic brain injury
  • • NA - 54 participants
  • • The clinical investigation aims to advance the Crainio device, designed for non-invasive intracranial pressure (ICP) monitoring

Who can take part?

  • • Ages 16 Years to 99 Years
  • • Diagnosed with traumatic brain injury

Where?

  • • London - Royal London Hospital

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The clinical investigation aims to advance the Crainio device, designed for non-invasive intracranial pressure (ICP) monitoring. This feasibility study involves 54 participants over a 12-month period and seeks to collect cerebral photoplethysmogram signals alongside concurrent invasive ICP measurements in patients with traumatic brain injury. The primary objective is to establish the diagnostic accuracy of the Crainio device, aiming for at least 90% sensitivity and specificity in detecting raised ICP (above 20 mmHg). Secondary objectives include evaluating patient-related factors such as skin tone, skull thickness, and skull density, as well as the tolerability and acceptance of the device by both patients and healthcare professionals.

More detail

Intracranial pressure (ICP) is routinely monitored in patients suffering from traumatic brain injury (TBI). Raised ICP can result in compression of the cerebral vasculature and subsequent reduction in oxygen and nutrient delivery to the brain leading to significant morbidity and mortality. In fact, raised ICP is the most common cause of death in patients with severe TBI. Standard ICP monitoring requires insertion of a cranial bolt into the skull through which an electrical transducer is inserted. Alternatively, an intra-ventricular catheter is inserted through a burr hole. Both of these monitoring methods are associated with risks including haemorrhage and infection, as well as delay in establishing emergency monitoring and limiting it to hospitals that have neurosurgery. There has been much research in recent years to find a method for measuring intracranial pressure noninvasively (nICP), including measurement of pressure in the retinal veins, measurement of eardrum displacement, transcranial Doppler ultrasonography and imaging-based solutions. These methods all require considerable user intervention and are non-continuous. This project aims to collect cerebral photoplethysmogram signals and concurrent invasive ICP measurements from patients with traumatic brain injury to develop Crainio machine learning (ML) algorithms. The core intellectual property (IP) of this continuous external monitoring ICP system was originally developed by academics in the lab of Professor Kyriacou at City, University of London. Crainio is a spin-out company that was created to industrialise and commercialise this research on an exclusive basis. The device comprises a forehead-mounted sensor containing infrared light sources that can illuminate the deep brain tissue of the frontal lobe. Photodetectors in the sensor detect the backscattered light, which is modulated by pulsation of the cerebral arteries. A control unit processes the backscattered light (called the photoplethysmogram, PPG) and transmits it to a computer device to train ML models that estimate an absolute value of ICP. The basic science behind this method for measuring ICP is that changes in the extramural arterial pressure affect the morphology of the recorded optical pulse, so analysis of the acquired signal using an appropriate algorithm will enable calculation of nICP. The reported nICP will provide screening at the triage stage, indicating the need for imaging or rapid intervention (such as haematoma evacuation) and guide head injury management, notably ICP-targeted treatment regimes. Ultimately this could lead to significant improvements in secondary injury-related mortality, length of hospital stay and reduced post-trauma disability. This feasibility study aims to collect the clinical data with which to train the nICP algorithms to the point that they can detect raised intracranial pressure (ICP\>20 mmHg) with sufficient sensitivity and specificity that Crainio device can be regulated for clinical use.

Traumatic Brain Injury

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 16 Years - 99 Years
  • Who can join: All genders

What the study is looking for

  • ✓Clinical diagnosis of traumatic brain injury.
  • ✓Adults (aged between 16 and 99, male and female)
  • ✓TBI patients admitted to the Royal London Hospital.
  • ✓Patients having invasive ICP monitoring as part of their normal medical treatment.

Who cannot take part

  • ✗Forehead skin is not intact.
  • ✗Decompressive craniectomy patients.
  • ✗Open external ventricular drainage (EVD) treatment.
  • ✗Patients who will unlikely survive the following twelve hours.
See the full criteria
Inclusion Criteria: * Clinical diagnosis of traumatic brain injury. * Adults (aged between 16 and 99, male and female) * TBI patients admitted to the Royal London Hospital. * Patients having invasive ICP monitoring as part of their normal medical treatment. Exclusion Criteria: * Forehead skin is not intact. * Decompressive craniectomy patients. * Open external ventricular drainage (EVD) treatment. * Patients who will unlikely survive the following twelve hours.

Where Is This Study? (1 UK site)

Royal London Hospital

London E1 1BB, United Kingdom

Recruiting
Site contact (verified)
Christopher Uff, DrPrincipal Investigator

How to Get in Touch

Jeremy Holland, Dr

Sponsor contact

CONTACT

0779 626 5994 Jeremy.Holland@crainio.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-03